WO1999062524A1 - Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs - Google Patents

Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs Download PDF

Info

Publication number
WO1999062524A1
WO1999062524A1 PCT/US1998/011748 US9811748W WO9962524A1 WO 1999062524 A1 WO1999062524 A1 WO 1999062524A1 US 9811748 W US9811748 W US 9811748W WO 9962524 A1 WO9962524 A1 WO 9962524A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glucosamine
dose
ranges
manganese
Prior art date
Application number
PCT/US1998/011748
Other languages
English (en)
Inventor
Robert W. Henderson
Tarek Hammad
Original Assignee
Nutramax Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutramax Laboratories, Inc. filed Critical Nutramax Laboratories, Inc.
Priority to PCT/US1998/011748 priority Critical patent/WO1999062524A1/fr
Priority to AU78227/98A priority patent/AU7822798A/en
Priority to JP2000551780A priority patent/JP2002516866A/ja
Priority to CA002333752A priority patent/CA2333752A1/fr
Priority to EP98926377A priority patent/EP1083906A4/fr
Publication of WO1999062524A1 publication Critical patent/WO1999062524A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to compositions for the repair and reduction of inflammation of connective tissue in humans and animals and, in particular, to compositions capable of promoting anti-inflammation, chondroprotection, chondromodulation, chondrostabilization, chondrometabolization and the repair and replacement of human and animal connective tissue.
  • afflictions such as arthritis, joint inflammation and stiffness.
  • connective tissue afflictions are quite common, presently affecting millions of Americans. Further, such afflictions can be not only painful but, in their extreme, debilitating.
  • connective tissue afflictions can be quite problematic. A simple decrease in the stress to which the connective tissue is subjected is often not an option, especially in the case of athletes and animals such as race horses. Consequently, treatment is often directed at controlling the symptoms of the afflictions and not their causes, regardless of the stage of the degenerative process.
  • steroids such as corticosteroids and NSAIDs
  • corticosteroids such as corticosteroids and NSAIDs
  • drugs such as these, which inhibit the body's own natural healing processes, may lead to further deterioration of the connective tissue.
  • Connective tissue for example articular cartilage
  • Connective tissue is naturally equipped to repair itself by manufacturing and remodeling prodigious amounts of collagen (a chief component of connective tissue such as cartilage) and proteoglycans (PGs) (the other major component of connective tissue such as cartilage).
  • collagen a chief component of connective tissue such as cartilage
  • proteoglycans the other major component of connective tissue such as cartilage.
  • This ongoing process is placed under stress when an injury occurs.
  • the production of connective tissue matrix (collagen and PGs) can double or triple over normal levels, thereby increasing the demand for the building blocks of both collagens and proteoglycans.
  • the building blocks for collagen are amino acids, especially proline, glycine and lysine.
  • PGs are large and complex macromolecules comprised mainly of long chains of modified sugars called glycosaminoglycans (GAGs) or mucopolysaccharides.
  • GAGs glycosaminoglycans
  • mucopolysaccharides are understood in the art to be interchangeable.
  • PGs provide the framework for collagen formation and also hold water to give flexibility, resiliency and resistance to compression.
  • the pathways by which both collagen and GAG form single molecule precursors are quite long.
  • the pathways by which collagen and GAGs are produced include what is called a rate-limiting step - that is, one highly regulated control point beyond which there is a commitment to finish.
  • the presence of such rate- limiting steps permits complicated biosynthetic processes to be more easily and efficiently controlled by permitting the organism to focus on one point. For example, if conditions demand production and all the requisite raw materials are in place, then stimulation of the rate-limiting step will cause the end product to be produced. To stop or slow production, the organism needs simply to regulate the rate-limiting step.
  • the rate-limiting step is the conversion of glucose to glucosamine for the production of GAGs.
  • Glucosamine an aminosugar, is the key precursor to all the various modified sugars found in GAGs, including glucosamine sulfate, galactosamine, N-acetylglucosamine, etc.
  • Glucosamine also makes up to 50% of hyaluronic acid ⁇ the backbone of PGs — on which other GAGs, like chondroitin sulfate are added.
  • the GAGs are then used to build PGs and, eventually, connective tissue. Once glucosamine is formed, there is no turning away from the synthesis of GAG polymers.
  • Glucosamine has been shown to be rapidly absorbed into humans and animals after oral administration. A significant portion of the ingested glucosamine localizes to cartilage and joint tissues, where it remains for long periods. This indicates that oral administration of glucosamine reaches connective tissues, where glucosamine is incorporated into newly-synthesized connective tissue.
  • Glycosaminoglycans and collagen are the chief structural elements of all connective tissues. Their synthesis is essential for proper maintenance and repair of connective tissues. In vitro, the introduction of glucosamine has been demonstrated to increase the synthesis of collagen and glycosaminoglycans in fibroblasts, which is the first step in repair of connective tissues. In vivo, topical application of glucosamine has enhanced wound healing. Glucosamine has also exhibited reproducible improvement in symptoms and cartilage integrity in humans with osteoarthritis. [L. Bucci, Nutritional Supplement Advisor, (July 1992)].
  • Glucosamine is the main building block of connective tissue and may be provided either through the enzymatic conversion of glucose or through diet or external administration (see FIG. 1). Glucosamine may be converted into the other main component of connective tissue, namely PGs, upon incorporation of glucosamine into GAGs (see FIG. 2).
  • GAGs are large complexes of polysaccharide chains associated with a small amount of protein. These compounds have the ability to bind large amounts of water, thereby producing a gel-like matrix that forms the body's ground substance. GAGs stabilize and support cellular and fibrous components of tissue while maintaining the water and salt balance of the body. The combination of insoluble protein and the ground substance forms connective tissue. For example, cartilage is rich in ground substance while tendon is composed primarily of fibers. GAGs are long chains composed of repeating disaccharide units of monosaccharides (aminosugar-acidic sugar repeating units). The aminosugar is typically glucosamine or galactosamine. The aminosugar may also be sulfated.
  • the acidic sugar may be D-glucuronic acid or L-iduronic acid.
  • GAGs with the exception of hyaluronic acid, are covalently bound to a protein, forming proteoglycan monomers. These PGs consist of a core protein to which linear carbohydrate chains formed of monosaccharides are attached. In cartilage proteoglycan, the species of GAGs include chondroitin sulfate and keratin sulfate. The proteoglycan monomers then associate with a molecule of hyaluronic acid to form PG aggregates. The association of the core protein to hyaluronic acid is stabilized by link proteins. The polysaccharide chains are elongated by the sequential addition of acidic sugars and aminosugars, and the addition is catalyzed by a family of transferases.
  • Aminosugars such as glucosamine
  • Aminosugars are synthesized through a series of enzymatic reactions that convert glucose to glucosamine, or alternatively may be provided through the diet.
  • the glucosamine is then incorporated into the GAGs as described above.
  • Acidic sugars may be provided through the diet, may be obtained through degradation of GAGs by degradative enzymes, or produced through the uronic acid pathway.
  • Chondroitin sulfate is a GAG that provides a further substrate for the synthesis of the proteoglycans.
  • the provision of the chondroitin in its salt (sulfate) form facilitates its delivery and uptake by the humans and animals in the production of connective tissue.
  • the sulfate portion of chondroitin sulfate is available for use in catalyzing the conversion of glucosamine to GAGs.
  • Fragments of GAGs, including chondroitin sulfate may also be used to provide a substrate for synthesis of proteoglycans since the assembly of PG occurs in the extracellular space.
  • glycosaminoglycan included in the compositions of the present invention is chondroitin sulfate or fragments thereof.
  • Chondroitin sulfate also acts to inhibit the degradative enzymes that break down connective tissue. In so doing, chondroitin sulfate promotes the maintenance of healthy connective tissues.
  • chondroitin sulfate works in concert with the glucosamine but may work in a different fashion. The ability of chondroitin sulfate to block degradation is one of its important functions.
  • SAM S-Adenosylmethionine
  • SAM plays a significant role in transmethylation processes with more than 40 anabolic or catabolic reactions involving the transfer of the methyl group of SAM to substrates such as nucleic acids, proteins, and lipids, among others. Also, the release of the methyl group from SAM is the start of a "transsulfuration" pathway that produces all endogenous sulfur compounds. After donating its methyl group, SAM is converted into S-adenosylhomocysteine, which in turn is hydrolyzed to adenosine and homocysteine. The amino acid cysteine may then be produced from the homocysteine.
  • the cysteine thus produced may exert a reducing effect by itself or as an active part of glutathione, which is a main cell anti-oxidant.
  • SAM has been used to treat various disorders. In various forms of liver disease,
  • SAM acts as an anticholestatic agent. [Adachi et al., Japan Arch. Inter. Med., 33:185-192 (1986)]. SAM has also been administered as an antidepressant for use in the management of psychiatric disorders [Caruso et al., Lancet, I : 904 (1984)], and as an anti- inflammatory compound in the management of osteoarthritis [Domljan et al., Int. J. Gin. Pharm. ToxicoL. 27f7):329-333 (1989)1.
  • SAM per se is unstable due to its high reactivity.
  • the relatively recent synthesis of stable salts has made SAM available for research and therapeutic use. [See, e.g., U.S. Patent Nos. 4,990,606 and 5,102,791].
  • SAM has been used outside of the United States in a number of clinical trials concerning the treatment of osteoarthritis. While used in these trials primarily as an analgesic and replacement for NSAID therapy, SAM is a precursor of polyamines. In addition to their analgesic and anti-inflammatory properties, and their ability to scavenge free radicals, polyamines may stabilize the polyanionic macromolecules of proteoglycans. [Schumacher, Am. J. Med.. 83(5A):2 (1987)]. SAM may also function as a source of endogenous sulfur, which will increase sulfation of GAGs to be incorporated in proteoglycans.
  • SAM is particularly beneficial in instances of subclinical deficiencies of SAM, occurring especially in elderly populations with higher risk of osteoarthritis [Frezza et al., Gastroenterol.. 99:211-215 (1990)].
  • the supplementation of SAM may aid in instances of SAM deficiency where the ability of the body to sulfate GAGs may be compromised.
  • a number of metabolites of SAM aid in the repair of connective tissue, including glutathione, polyamines, methylthioadenosine, and adenosine.
  • Glutathione works as a scavenger of oxygen-related products [Shumacher, Am. J. Med., 83(Supp
  • glycosyltransferases are important in glycosaminoglycan synthesis (hyaluronic acid, chondroitin sulfate, keratan sulfate, heparin sulfate and dermatin sulfate, etc.), collagen synthesis, and in the functions of many other glycoproteins and glycolipids.
  • Manganese deficiency leads to abnormal bone growth, swollen and enlarged joints, and slipped tendons in humans and animals. In humans, manganese deficiencies are also associated with bone loss and arthritis. Levels of all glycosaminoglycans are decreased in connective tissues during manganese deficiencies, with chondroitin sulfates being most depleted. Manganese-deficient organisms quickly normalize glycosaminoglycans and collagen synthesis when manganese is replenished.
  • methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine.
  • vitamins B12 and B6 folic acid
  • dimethylglycine dimethylglycine
  • trimethylglycine trimethylglycine
  • these compounds augment the function of SAM in that they are cofactors in methylation.
  • these compounds are likely to be lacking in patients suffering from connective tissue disorders. For example, it is estimated that 12% of the elderly population in the United States suffers from a vitamin B12 deficiency, a group more likely to suffer from connective tissue disorders.
  • vitamin B12 has an important environmental influence on the accumulation of homocysteine that results from the metabolism of SAM.
  • methyl donors or methyl donor cofactors such as vitamin B12 and the others listed in the preceding paragraph, can reduce levels of homocysteine when administered either alone or in combination.
  • Vitamin B12 is generally known to function as a coenzyme in biochemical reactions such as the synthesis of proprionic acid and of methionine. Recent evidence suggests that the elevated levels of plasma homocysteine increase the risk of occlusive vascular disease. Adequate amounts of vitamin B 12 are considered the most important environmental influence on the accumulation of unnecessary homocysteine. [Joosten et al, Am. J. Clin. Nutr.. 58(4): 468-76 (1993)]. In addition, it is also understood that vitamin B12 may play a role in the methylation of selenium. [Chen and Whanger, Tox. and Appl. Pharm., 118:65-72 (1993)]. Specifically, increased levels of vitamin B12 significantly contribute to selenium methylation and might decrease overall selenium toxicity by preventing its accumulation in tissues. [Chen and Whanger, cited above]. 3. Description of Background Art
  • glucosamine a precursor of the GAGs
  • glucosamine a precursor of the GAGs
  • glucosamine a precursor of the GAGs
  • the intravenous administration of glucosamine and derivatives thereof has been disclosed in United States Patent No. 3,232,836, issued to Carlozzi et al., for assisting in the healing of wounds on the surface of the body.
  • United States Patent No. 3,682,076, issued to Rovati the use of glucosamine and salts thereof is disclosed for the treatment of arthritic conditions.
  • glucosamine salts has also been disclosed for the treatment of inflammatory diseases of the gastrointestinal tract in United States Patent No.
  • 4,486,416 issued to Soil et al. discloses a method of protecting corneal endothelial cells exposed to the trauma of intraocular lens implantation surgery by administering a prophylactically effective amount of chondroitin sulfate.
  • United States Patent No. 5,141,928 issued to Goldman discloses the prevention and treatment of eye injuries using glycosaminoglycan polysulfates.
  • compositions which include analgesic, anti-inflammatory, and antidepressant components, as well as components that provide the building blocks for the production of connective tissue in humans and that also protect against the degradation of that tissue.
  • compositions which contain S-Adenosylmethionine and an aminosugar or salts thereof, such as glucosamine, for facilitating the repair and reducing the inflammation of connective tissue in humans and animals.
  • compositions which contain S-Adenosylmethionine and GAGs, such as chondroitin salts and fragments thereof, for facilitating the repair and for reducing the inflammation of connective tissue in humans and animals.
  • compositions which contain S-Adenosylmethionine, an aminosugar or salts thereof, and GAGs or fragments thereof for facilitating the repair and for reducing the inflammation of connective tissue in humans and animals.
  • methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine, to the compositions of the present invention for humans and animals if desirable. It is a further object of the present invention to provide methods of administering these compositions.
  • FIG. 1 is a sequence for the biosynthesis of hexosamines.
  • FIG. 2 is a schematic flowchart illustrating the biological pathway by which the composition of the present invention aids in protection and repair of connective tissue.
  • FIG. 3 is an enlarged portion of the flowchart of FIG. 2.
  • a composition selected from the group consisting of SAM and an aminosugar or salts thereof e.g., glucosamine
  • SAM and GAGs e.g., chondroitin salts
  • SAM, an aminosugar (or salts thereof), and GAGs (or fragments thereof) is provided to humans and animals for stimulating both collagen and PG synthesis and for reducing inflammation.
  • Manganese preferably manganese salts, may optionally be included to any of these compositions.
  • other optional ingredients include methyl donors or methyl donor cofactors, such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine.
  • compositions may act to accomplish several functions, including bypassing the glucose to glucosamine rate-limiting step in the natural production of proteoglycans in humans and animals, and producing additional quantities of collagen and proteoglycans for use in the repair of damaged connective tissue.
  • inflammation of connective tissue may be reduced by the compositions of the invention.
  • the compositions of the present invention may achieve these functions directly or through indirect pathways -- i.e., through their effect on other components in the living system which in turn can increase connective tissue synthesis or reduce inflammation.
  • a composition of the present invention include S- Adenosylmethionine (SAM) and an aminosugar, such as glucosamine, preferably in a salt form.
  • SAM S- Adenosylmethionine
  • the composition includes SAM and a glycosaminoglycan, such as chondroitin (preferably in a salt form such as chondroitin sulfate).
  • the composition of the present invention includes SAM, an aminosugar, such as glucosamine, preferably in a salt form, and a glycosaminoglycan, such as chondroitin (preferably in a salt form, such as chondroitin sulfate).
  • fragments of a glycosaminoglycan may be used in a composition of the invention in addition to or in substitution for the glycosaminoglycan.
  • Each of these compositions may optionally include manganese.
  • a preferred form of manganese in such compositions is a manganese salt, such as manganese ascorbate, because the ascorbate is a soluble form of manganese which further provides ascorbic acid, a substance needed for collagen synthesis.
  • Other manganese salts such, as for example, sulfate or gluconate, may be used however.
  • compositions may optionally contain one or more methyl donors or methyl donor cofactors selected from the group consisting of vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine.
  • methyl donors or methyl donor cofactors selected from the group consisting of vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine.
  • the aminosugar glucosamine is the base of the composition, providing the primary substrate for both collagen and proteoglycan synthesis.
  • Glucosamine is the preferred substrate for proteoglycan synthesis, including chondroitin sulfates and hyaluronic acid.
  • the glucosamine preferably is in a salt form so as to facilitate its delivery and uptake by humans and animals.
  • the preferred salt forms are glucosamine hydrochloride, glucosamine sulfate and N-acetylglucosamine.
  • composition of the present invention provides the human or animal organism with exogenous quantities of SAM, an aminosugar or salts thereof, and a glycosaminoglycan or fragments thereof. If desired, the composition also provides the human or animal organism with exogenous quantities of manganese cofactors. Also if desired, the compositions of the present invention may include methyl donors or methyl donor cofactors, such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine.
  • exogenous glucosamine provided by the composition of present invention is converted to proteoglycans as is seen in FIG. 2 and as described above.
  • the glucosamine may be converted with the aid of manganese directly into GAG, including hyaluronic acid (which is 50%> glucosamine and which forms the backbone of the proteoglycans).
  • hyaluronic acid which is 50%> glucosamine and which forms the backbone of the proteoglycans.
  • This core protein is then linked to the hyaluronic acid via the link protein, as is seen in FIG. 3.
  • the free amino acids are, with the aid of manganese and zinc cofactors (and ascorbic acid or vitamin C), converted to procollagen.
  • the procollagen is then converted into collagen with the aid of copper or iron cofactors and vitamin C (ascorbic acid) and sulfate chelates.
  • compositions of the present invention containing SAM and glucosamine advantageously stimulate the synthesis of collagen and glycosaminoglycans or mucopolysaccharides (GAGs), including hyaluronic acid, the backbone of proteoglycans (PGs), thereby providing a natural tissue repair function.
  • GAGs glycosaminoglycans or mucopolysaccharides
  • PGs proteoglycans
  • manganese provides a further benefit if a deficiency of the mineral exists or if it is otherwise desired.
  • methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine, helps to promote methylation and thereby convert homocysteine to methionine.
  • compositions of the invention comprises SAM and chondroitin salts (such as chondroitin sulfate).
  • SAM operates in this composition, in conjunction with endogenous glucosamine, as described above.
  • Chondroitin salts operate with SAM and endogenous glucosamine by inhibiting the synovial degradative enzymes.
  • Chondroitin salts (such as chondroitin sulfate) also directly contribute to the pool of GAGs of cartilaginous tissue.
  • Manganese salts may also be included in this composition in those cases where a deficiency of manganese exists.
  • Methyl donors or methyl donor cofactors such as vitamins B12 and B6.
  • folic acid, dimethylglycine, and trimethylglycine may optionally be included in these compositions to help promote methylation and thereby convert homocysteine to methionine.
  • composition of the present invention contains SAM, glucosamine, and chondroitin salts (such as chondroitin sulfate) and mixtures and fragments thereof, and also advantageously stimulates the synthesis of collagen and glycosaminoglycans or mucopolysaccharides (GAGs), including hyaluronic acid, thereby providing a natural tissue repair function.
  • This composition provides the superior connective tissue repair function of glucosamine, the above-described benefits of SAM, and the above-described benefits from chondroitin salts (including chondroitin sulfate) and fragments of chondroitin salts.
  • Chondroitin salts (including chondroitin sulfate) also operate with SAM and glucosamine by inhibiting the synovial degradative enzymes. Chondroitin salts (including chondroitin sulfate) also directly contribute to the pool of GAGs of cartilaginous tissue. Manganese provides a further benefit if a deficiency of the mineral exists.
  • methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine, may optionally be included in these compositions to help promote methylation and thereby convert homocysteine to methionine. Tissue repair can thus be accomplished, in the context of the treatment and repair of connective tissue and the treatment of arthritic conditions, in almost all areas of the body both human and animal.
  • compositions comprising amounts of SAM in combination with glucosamine including salts thereof in combination with chondroitin salts (including chondroitin sulfate) or fragments thereof, or amounts of SAM and chondroitin salts (including chondroitin sulfate) or fragments thereof in combination with glucosamine including salts thereof, may be administered to humans and animals thereof for stimulating both collagen and proteoglycan synthesis.
  • An additional preferred composition comprising amounts of SAM and chondroitin salts (including chondroitin sulfate) or fragments thereof may be admimstered to humans and animals for stimulating proteoglycan synthesis and reducing inflammation.
  • Manganese salts may also be optionally included in each composition in cases where a deficiency of manganese exists.
  • Methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine may optionally be included to these compositions as well.
  • the compositions of the present invention are administered to promote tissue repair, including cartilage repair, and the treatment of arthritic conditions as well as connective tissue damage in humans and animals.
  • the anti-depressant effect of SAM may help to alleviate the burden of sickness for some patients, thus enhancing their quality of life.
  • compositions of the present invention are also understood to play a role in chondromodulation, chondrostabilization, and chondrometabolizaton.
  • the dosage of SAM in the nutritional supplements of the present invention ranges from about 5 mg to about 5,000 mg in humans and small animals, and from about 2 mg to about 20,000 mg in large animals (e.g., equine).
  • the dosage of glucosamine in the nutritional supplements of the present invention ranges from about 50 mg to about 5,000 mg in humans and small animals, and from about 250 mg to about 40,000 mg in large animals (e.g., equine).
  • the dosage of chondroitin salts in the nutritional supplements of the present invention ranges from about 15 mg to about 5,000 mg in humans and small animals, and from about 100 mg to about 30,000 mg in large animals.
  • manganese When included in the compositions of the present invention, manganese may optionally be present in the range of about 2 to about 75 mg in humans and small animals, and from about 10 mg to about 500 mg in large animals.
  • the ascorbate component of the manganese ascorbate may range from about 10 mg to about 500 mg in humans and small animals, and from about 50 mg to about 2,500 mg in large animals.
  • the methyl donors or methyl donor cofactors such as vitamins B12 and B6, folic acid, dimethylglycine, and trimethylglycine may be present in the range of about 0.1 mg to about 10 mg in humans and small animals, and from about 1 mg to about 100 mg in large animals.
  • a dosage of the nutritional supplement composition of the present invention may consist of one or more capsules or tablets for human oral consumption.
  • the preferred weight of the dosage is between about 5 mg to about 5,000 mg, and preferably about 2,500 mg.
  • the dosage may be administered in a single daily dosage form in which all components are present, e.g., a capsule or tablet of preferably 2,500 mg.
  • the dosage may also be administered in more than one dosage form in which each dosage form contains at least one component.
  • the multiple dosage forms may be co-administered as a single dosage.
  • a single dosage may be comprised of a SAM dosage form co-administered with a glucosamine and chondroitin salts dosage form.
  • the nutritional supplement compositions of the present invention may be administered more than once daily.
  • the nutritional supplement compositions of the present invention may be in the form of an oral dosage form of 1250 mg administered twice daily or 833 mg administered three times daily.
  • the number of daily administrations will depend upon the needs of the human or animal recipient. Different connective tissue disorders and injuries require different amounts of the compositions of the present invention. In that regard, several dosages may be administered depending on the particular needs of the human or animal.
  • compositions of the present invention may for example be administered in scoops.
  • Such administration may take the form, for example, of a level scoopful containing about 1,800 mg glucosamine, about 600 mg chondroitin salts, about 16 mg of manganese (when included in the form of manganese ascorbate), and about 104 mg of ascorbate (when included in the form of manganese ascorbate).
  • a suitable carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., oral, sublingual, nasal, guttural, rectal, transdermal or parenteral.
  • any usual pharmaceutical medium may be employed.
  • oral liquid preparations e.g., suspensions, elixirs, and solutions
  • media containing for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used.
  • Carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to prepare oral solids (e.g., powders, capsules, pills, caplets, tablets, microencapsulated granules, microtablets, coated granules and lozenges).
  • Capsules or tablets are a preferred oral dosage form. Controlled release forms may also be used.
  • compositions of the present invention may be in the form of one or more of these oral dosage forms ⁇ i.e., a single dosage may be in multiple forms.
  • the carrier will usually comprise sterile water, although other ingredients may be included, e.g., to aid solubility or for preservation purposes.
  • injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.
  • each dosage contains:
  • each dosage contains:
  • Example 1 For larger animals, such as horses, the composition of Example 1 is administered as filled scoops.
  • EXAMPLE 4 For those situations in which manganese supplementation is desired, manganese salts may be added to the composition of Example 3 so that each dosage contains: Large Animal (Equine) Range/Dose SAM 2-20,000 mg
  • each dosage contains: Human & Small Animal Range/Dose
  • a manganese salt is added to the composition of Example 5 so that each dosage contains: Human & Small Animal Range/Dose SAM 5-5,000 mg
  • Example 5 For larger animals, such as horses, the composition of Example 5 is administered as filled scoops.
  • manganese salts may be added to the composition of Example 7 so that each dosage contains:
  • each dosage contains:
  • a manganese salt is added to the composition of Example 9 so that each dosage contains: Human & Small Animal Range/Dose
  • Example 10 For larger animals, such as horses, the composition of Example 10 is administered as filled scoops.
  • EXAMPLE 12 For those situations in which manganese supplementation is desired, manganese salts may be added to the composition of Example 11 so that each dosage contains: Large Animal (Equine) Range/Dose
  • EXAMPLE 13 For those situations in which methyl donors or methyl donor cofactors are desired, such compounds may be added to the composition of Example 1 so that each dosage contains:
  • a manganese salt is added to the composition of Example 13 so that each dosage contains: Human & Small Animal Range/Dose
  • EXAMPLE 15 For larger animals, such as horses, the composition of Example 13 is administered as filled scoops. Large Animal (Equine) Range/Dose
  • EXAMPLE 16 For those situations in which manganese supplementation is desired, manganese salts may be added to the composition of Example 15 so that each dosage contains: Large Animal (Equine) Range/Dose
  • each dosage contains:
  • each dosage contains:
  • Ascorbate (as Manganese Ascorbate) 10-500 mg vitamin B12 0.1-10 mg
  • Example 17 For larger animals, such as horses, the composition of Example 17 is administered as filled scoops.
  • manganese salts may be added to the composition of Example 19 so that each dosage contains: Large Animal (Equine) Range/Dose
  • each dosage contains: Human & Small Animal Range/Dose
  • EXAMPLE 22 For those situations in which manganese supplementation is desired, a manganese salt is added to the composition of Example 21 so that each dosage contains: Human & Small Animal Range/Dose
  • Example 21 For larger animals, such as horses, the composition of Example 21 is administered as filled scoops.
  • manganese salts may be added to the composition of Example 23 so that each dosage contains:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à une composition servant à la protection, au traitement et à la réparation des tissus conjonctifs et servant à réduire l'inflammation de ces tissus conjonctifs chez des mammifères, ainsi qu'à un procédé de traitement des tissus conjonctifs chez des mammifères par administration de cette composition. Celle-ci contient de la S-adénosylméthionine (SAM), ainsi qu'un constituant choisi parmi un aminosucre ou des sels de celui-ci (par exemple glucosamine) ou des glycosaminoglycanes (par exemple des sels de chondroïtine) ou des mélanges ou fragments de ceux-ci. Cette composition renferme en option du manganèse qui favorise la production de matrices de tissus conjonctifs. Cette composition renferme également en option des donneurs méthyliques ou des cofacteurs de donneurs méthyliques, tels que la vitamine B12, la vitamine B6, l'acide folique, la diméthylglycine ou la triméthylglycine.
PCT/US1998/011748 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs WO1999062524A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/US1998/011748 WO1999062524A1 (fr) 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs
AU78227/98A AU7822798A (en) 1998-06-04 1998-06-04 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
JP2000551780A JP2002516866A (ja) 1998-06-04 1998-06-04 結合組織を治療し修復するためのアミノ糖、グリコサミノグリカンおよびｓ−アデノシルメチオニン組成物
CA002333752A CA2333752A1 (fr) 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs
EP98926377A EP1083906A4 (fr) 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/011748 WO1999062524A1 (fr) 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs

Publications (1)

Publication Number Publication Date
WO1999062524A1 true WO1999062524A1 (fr) 1999-12-09

Family

ID=22267258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/011748 WO1999062524A1 (fr) 1998-06-04 1998-06-04 Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs

Country Status (5)

Country Link
EP (1) EP1083906A4 (fr)
JP (1) JP2002516866A (fr)
AU (1) AU7822798A (fr)
CA (1) CA2333752A1 (fr)
WO (1) WO1999062524A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083151A2 (fr) * 2000-12-14 2002-10-24 Tufts University Compositions et procedes pour traiter un etat arthritique
WO2003053412A1 (fr) * 2001-12-12 2003-07-03 Chemistry & Health International B.V. Granules stables contenant de la s-adenosylmethionne et leur procede de preparation
EP1328278A1 (fr) * 2000-09-26 2003-07-23 Temple University of the Commonwealth System of Higher Education Analgesique et compositions de glucosamine
JP2004506007A (ja) * 2000-08-16 2004-02-26 アールエス・オーエルディーシーオー・インコーポレイテッド 錠剤の製造法及びそれから作られる錠剤組成物
WO2005077386A1 (fr) * 2004-02-09 2005-08-25 Hill's Pet Nutrition, Inc. Composition et methode destinees a etre utilisees pour le traitement de troubles affectant le cartilage
KR100861430B1 (ko) * 2000-11-10 2008-10-02 로도세이야구가부시기가이샤 제제 및 그의 제조 방법
JP2013032406A (ja) * 2012-11-22 2013-02-14 Rohto Pharmaceutical Co Ltd アミノ糖含有製剤
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
JP2014139254A (ja) * 2014-05-08 2014-07-31 Rohto Pharmaceut Co Ltd アミノ糖含有製剤
US8968791B2 (en) 2007-06-06 2015-03-03 Novus International, Inc. Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
JP2015172094A (ja) * 2015-07-10 2015-10-01 ロート製薬株式会社 アミノ糖含有製剤
JP2016222726A (ja) * 2016-10-03 2016-12-28 ロート製薬株式会社 アミノ糖含有製剤
JP2017214432A (ja) * 2017-09-15 2017-12-07 ロート製薬株式会社 アミノ糖含有製剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4739705B2 (ja) * 2004-07-21 2011-08-03 ロート製薬株式会社 内服用組成物
JP6736251B2 (ja) * 2014-10-31 2020-08-05 小林製薬株式会社 経口組成物
JP2018199728A (ja) * 2018-09-26 2018-12-20 小林製薬株式会社 経口組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587363A (en) * 1993-03-31 1996-12-24 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2240165A1 (fr) * 1995-12-11 1997-06-19 Inholtra, Inc. Regime alimentaire a base de complements nutritionnels permettant de soulager les symptomes de l'arthrite
AU4941297A (en) * 1996-11-15 1998-06-10 Dumex-Alpharma A/S A method for promoting tissue repair
US6255295B1 (en) * 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587363A (en) * 1993-03-31 1996-12-24 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1083906A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506007A (ja) * 2000-08-16 2004-02-26 アールエス・オーエルディーシーオー・インコーポレイテッド 錠剤の製造法及びそれから作られる錠剤組成物
EP1328278A1 (fr) * 2000-09-26 2003-07-23 Temple University of the Commonwealth System of Higher Education Analgesique et compositions de glucosamine
EP1328278A4 (fr) * 2000-09-26 2004-06-16 Univ Temple Analgesique et compositions de glucosamine
US6900189B2 (en) 2000-09-26 2005-05-31 Robert Raffa Analgesic and glucosamine compositions
KR100861430B1 (ko) * 2000-11-10 2008-10-02 로도세이야구가부시기가이샤 제제 및 그의 제조 방법
WO2002083151A3 (fr) * 2000-12-14 2003-05-01 Univ Tufts Compositions et procedes pour traiter un etat arthritique
WO2002083151A2 (fr) * 2000-12-14 2002-10-24 Tufts University Compositions et procedes pour traiter un etat arthritique
WO2003053412A1 (fr) * 2001-12-12 2003-07-03 Chemistry & Health International B.V. Granules stables contenant de la s-adenosylmethionne et leur procede de preparation
EP1325740A1 (fr) * 2001-12-12 2003-07-09 Chemistry & Health International B.V. Granules stables contenant de la s-adenosylmethionine et procede de preparation
US7048948B2 (en) 2001-12-12 2006-05-23 Chemistry & Health Int Bv Stable granulates containing S-adenosylmethionine and process for the preparation thereof
WO2005077386A1 (fr) * 2004-02-09 2005-08-25 Hill's Pet Nutrition, Inc. Composition et methode destinees a etre utilisees pour le traitement de troubles affectant le cartilage
AU2005212363B2 (en) * 2004-02-09 2010-12-23 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US8968791B2 (en) 2007-06-06 2015-03-03 Novus International, Inc. Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
JP2013032406A (ja) * 2012-11-22 2013-02-14 Rohto Pharmaceutical Co Ltd アミノ糖含有製剤
JP2014139254A (ja) * 2014-05-08 2014-07-31 Rohto Pharmaceut Co Ltd アミノ糖含有製剤
JP2015172094A (ja) * 2015-07-10 2015-10-01 ロート製薬株式会社 アミノ糖含有製剤
JP2016222726A (ja) * 2016-10-03 2016-12-28 ロート製薬株式会社 アミノ糖含有製剤
JP2017214432A (ja) * 2017-09-15 2017-12-07 ロート製薬株式会社 アミノ糖含有製剤

Also Published As

Publication number Publication date
EP1083906A1 (fr) 2001-03-21
EP1083906A4 (fr) 2003-03-26
CA2333752A1 (fr) 1999-12-09
AU7822798A (en) 1999-12-20
JP2002516866A (ja) 2002-06-11

Similar Documents

Publication Publication Date Title
US6583123B2 (en) Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
EP1849471B1 (fr) Compositions contenant de sucre aminé, de la chondroitine et de S-adénosylméthionine
AU688313B2 (en) Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
US6645948B2 (en) Nutritional composition for the treatment of connective tissue
US6476005B1 (en) Oral and injectable nutritional composition
WO1999062524A1 (fr) Composition a base d'aminosucre, de glycosaminoglycane et de s-adenosylmethionine pour le traitement et la reparation des tissus conjonctifs
MXPA06002526A (es) Composicion y metodo para facilitar la curacion de huesos.
US20050113287A1 (en) Composition to enhance joint function and repair
AU3438500A (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
GB2286528A (en) Dietary supplement
CA2446615C (fr) Composition nutritionnelle pour le traitement du tissu conjonctif
AU2007262359A1 (en) Compositions and kits comprising a melatonin component and a chondroprotective component
Petito The Role of hyCURE® and Other Chondroprotective Agents in Oral Dietary Supplements
CA2307079A1 (fr) Compositions utiles pour le traitement de maladies du tissu conjonctif

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998926377

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 78227/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2333752

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1998926377

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998926377

Country of ref document: EP